Myocardial Infarction News and Research

RSS

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

Two key, independent proof-of-concept studies conducted for NellOne Therapeutics, Inc. demonstrate the potential efficacy of the company’s lead therapeutic candidate for both skeletal muscle wound healing and myocardial infarction.

26 Mar 2010

NIH grants $1.4 Million to WPI to continue study of arterial plaque

A Worcester Polytechnic Institute research team has received a four-year, $1.4 million award from the National Institutes of Health to continue a groundbreaking study of arterial plaque. This research could lead to tools that will enable physicians to predict the likelihood of plaque rupture, which is responsible for most heart attacks and strokes.

25 Mar 2010

Genetic variation associated with lower risk of sudden cardiac arrest:Study

Physician-scientists at the Cedars-Sinai Heart Institute have found that a genetic variation is associated with lower risk of sudden cardiac arrest, a disorder that gives little warning and is fatal in about 95 percent of cases. Findings will be published tomorrow by the Public Library of Science (PloS One).

25 Mar 2010

Cancer radiotherapy can increase risk of cardiovascular disease later in life

For an as yet unknown reason, cancer radiotherapy can increase the risk of cardiovascular disease later in life, a problem that is growing as more and more people survive their cancer diagnosis. New research from Karolinska Institutet now suggests that sustained inflammation induced by post-radiotherapy changes in the gene expression in the arteries could be the cause.

22 Mar 2010

China Sky One Medical's Myocardial Infarction and Urine Microalbumin Diagnostic Kits receive CE certification

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the receipt of Conformite Europeenne (CE) certification for its Myocardial Infarction and Urine Microalbumin Diagnostic Kits. The CE marking certifies that the two products have met the European Union health and safety standards and are approved for sale in the 27 EU countries and four members of the European Free Trade Association.

20 Mar 2010

Innovative tissue damage preventing cardiac scaffold awarded Rappaport Prize for biomedical research

Prof. Smadar Cohen, head of the University's Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, has been awarded the prestigious Rappaport Prize for Excellence in Biomedical Research, an award totaling $100,000. The prize, given by Israel's Rappaport Foundation, is presented annually to a researcher whose research has either significantly advanced or has the potential to significantly advance any medical or biomedical field.

20 Mar 2010

Despite recommendations, nearly 14% of Medicare beneficiaries with STEMI undergo multi-vessel PCI

Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) undergo multi-vessel primary percutaneous coronary intervention (PCI), despite recommendations from the American College of Cardiology and the American Heart Association to intervene on only the culprit vessel.

19 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

18 Mar 2010

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.

18 Mar 2010

Studies link atmospheric CO pollution to adverse cardiovascular outcomes, cardiac mortality

In the healthy rat, prolonged exposure to carbon monoxide (CO) under conditions that mimic urban pollution leads to changes to cardiac morphology and function. Compensatory mechanisms develop in these animals to sustain normal cardiac activity, but they become more vulnerable to heart disease.

18 Mar 2010

AstraZeneca's CRESTOR: Health Canada approves new indication

AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.

17 Mar 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

Primary results of CABG sub-analysis presented at ACC meeting

AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA™/BRILIQUE™) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.

17 Mar 2010

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Boston Scientific Corporation today announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS® Element™ Paclitaxel-Eluting Stent System compared to the TAXUS® Express2™ Paclitaxel-Eluting Stent System.

16 Mar 2010

Medtronic' Endeavor DES demonstrates safety and efficacy profile for coronary artery disease treatment

The consistency and quality of the long-term clinical results for the Endeavor® drug-eluting stent (DES) from Medtronic, Inc., continue to distinguish it as a treatment for coronary artery disease, according to newly released data.

16 Mar 2010

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Boston Scientific Corporation today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the Express® bare-metal stent.

16 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER® Sirolimus-eluting Coronary Stent and Medtronic’s Endeavor® Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

16 Mar 2010

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

St. Jude Medical, Inc., a global medical device company, announced several updates to its PressureWire™ platform, including a new marketing agreement with Siemens Medical Solutions USA, for the wireless PressureWire™ Aeris and the availability of the next-generation of PressureWire™ Certus technology, at the American College of Cardiology and the Society of Interventional Radiology annual meetings.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

New trial comparing drug-eluting stents to bypass graft surgery in left main coronary artery disease patients

The announcement of a new clinical trial, EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), that will compare drug-eluting stents to coronary artery bypass graft surgery in patients with left main coronary artery disease, was made today at "Optimizing PCI Outcomes: Evolving Paradigms," a symposium presented by the Cardiovascular Research Foundation.

15 Mar 2010

Myocardial Infarction News and Research

NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy

NIH grants $1.4 Million to WPI to continue study of arterial plaque

Genetic variation associated with lower risk of sudden cardiac arrest:Study

Cancer radiotherapy can increase risk of cardiovascular disease later in life

China Sky One Medical's Myocardial Infarction and Urine Microalbumin Diagnostic Kits receive CE certification

Innovative tissue damage preventing cardiac scaffold awarded Rappaport Prize for biomedical research

Despite recommendations, nearly 14% of Medicare beneficiaries with STEMI undergo multi-vessel PCI

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

Studies link atmospheric CO pollution to adverse cardiovascular outcomes, cardiac mortality

AstraZeneca's CRESTOR: Health Canada approves new indication

Pathway Genomics' personal Genetic Health Report now available

Primary results of CABG sub-analysis presented at ACC meeting

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Medtronic' Endeavor DES demonstrates safety and efficacy profile for coronary artery disease treatment

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

CYPHER Sirolimus-eluting Coronary Stent provides better outcome compared to Medtronic’s Endeavor Stent

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

New trial comparing drug-eluting stents to bypass graft surgery in left main coronary artery disease patients

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News